A detailed history of Hhlr Advisors, Ltd. transactions in Legend Biotech Corp stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 6,636,496 shares of LEGN stock, worth $218 Million. This represents 7.41% of its overall portfolio holdings.

Number of Shares
6,636,496
Previous 6,636,496 -0.0%
Holding current value
$218 Million
Previous $294 Million 10.02%
% of portfolio
7.41%
Previous 7.6%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$39.5 - $57.22 $25.8 Million - $37.3 Million
651,946 Added 10.89%
6,636,496 $294 Million
Q4 2023

Feb 14, 2024

SELL
$57.25 - $69.74 $25.9 Million - $31.5 Million
-451,983 Reduced 7.02%
5,984,550 $360 Million
Q2 2023

Aug 14, 2023

BUY
$46.28 - $75.01 $60.4 Million - $98 Million
1,306,166 Added 25.46%
6,436,533 $444 Million
Q1 2023

May 15, 2023

SELL
$43.42 - $57.37 $271,375 - $358,562
-6,250 Reduced 0.12%
5,130,367 $247 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $26.7 Million - $40 Million
700,000 Added 15.78%
5,136,617 $210 Million
Q2 2022

Aug 15, 2022

SELL
$33.54 - $55.0 $83.9 Million - $138 Million
-2,500,000 Reduced 36.04%
4,436,617 $244 Million
Q1 2022

May 16, 2022

SELL
$31.02 - $48.18 $151 Million - $235 Million
-4,868,308 Reduced 41.24%
6,936,617 $252 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $30.9 Million - $42.7 Million
750,000 Added 6.78%
11,804,925 $550 Million
Q3 2021

Nov 15, 2021

BUY
$35.31 - $50.56 $367 Million - $526 Million
10,404,925 Added 1600.76%
11,054,925 $559 Million
Q2 2020

Aug 14, 2020

BUY
$36.1 - $42.56 $23.5 Million - $27.7 Million
650,000 New
650,000 $27.7 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Hhlr Advisors, Ltd. Portfolio

Follow Hhlr Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Hhlr Advisors, Ltd. with notifications on news.